The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes I don't use this either, just noticed when cross referencing.
I'm going to say our results will be the same as this;
"Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile were consistent with the Company's own Phase II trial (SG005). "
That, as well. :)
No idea but I do not rely on LSE for RNS info. It sometimes takes LSE a day or so to publish new ones. The company or London Stock Exchange websites are much more reliable.
This website is ****? :p
Ok well I wonder why the RNS is NOT on this website.?
The RNS has not been removed. It is on the Synairgen website and has been there since Apil 2017.
Wonder why this RNS has been removed? Astrazeneca cancelled their P2 trial but it left positive data for us. Expecting positive results coming here now.
https://markets.ft.com/data/announce/full?dockey=1323-13206094-0G2UV3F6787OLFH4CT3HTRNKEJ
Synairgen PLC
AZD9412 Update
April 27, 2017Source: RNS
RNS Number : 4767D
Synairgen plc
27 April 2017
Press release
Synairgen plc
('Synairgen' or the 'Company')
AZD9412 Update
· Cold infections did not affect trial patients' asthma in the INEXAS study as much as predicted, meaning that the drug's effects on severe exacerbations could not be determined
· Treatment with AZD9412 switched on antiviral responses in the lungs, improved morning peak flow (a measure of lung function), and was well tolerated
· The study however, did not meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen
· Synairgen will conduct further analysis of the data and determine future development routes
Southampton, UK - 27th April 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today provides an update on AZD9412 (inhaled interferon beta).
In October 2016 Synairgen provided the market with an update on the INEXAS trial of AZD9412, a novel, inhaled interferon beta that supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections (primarily common cold viruses). The trial was stopped early due to a low severe exacerbation event rate which compromised an assessment of this endpoint (number of severe exacerbations).
Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile were consistent with the Company's own Phase II trial (SG005).
The study did not however meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen.
Further analysis of samples from the trial is being completed by AstraZeneca. Data from this sample analysis and the clinical trial data will be licensed to Synairgen. Synairgen will complete the data analysis and will use this as a basis to determine the future direction of the programme.
Professor Stephen Holgate CBE, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton, said: "We believe that the biomarker, lung function and safety data from this and our previous study continue to support the potential of inhaled interferon beta as a treatment for vulnerable patients whose disease control is badly affected when they get a cold. We are particularly interested in the potential for COPD, where exacerbations are associated with disease progression and an increased risk of dying. Since we licensed this programme to AstraZeneca, the weight of data linking viruses